Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2004-01-08
2008-12-16
Chen, Stacy B (Department: 1648)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S069100, C435S320100, C424S199100, C424S211100
Reexamination Certificate
active
07465794
ABSTRACT:
Recombinant respiratory syncytial virus (RSV) are provided which express one or more immune modulatory molecules. The recombinant virus is modified by addition or substitution of a polynucleotide sequence encoding the immune modulatory molecule, which is preferably a cytokine. Introduction of the cytokine increase, decrease, or otherwise enhances aspects of viral biology and/or host immune responses to RSV to facilitate vaccine use of the virus. Cytokines for use within the invention include but are not limited to interleukin 2 (IL-2), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL6), or interleukin 18 (IL-18), tumor necrosis factor (TNF) alpha, interferon gamma (IFN), and granulocyte-macrophage colony stimulating factor (GM-CSF). The polynucleotide or immune modulatory molecule is preferably added or substituted into the recombinant viral genome or antigenome, typically at an intergenic or other non-coding site, as a separate gene but may be otherwise expressed, for example as a fusion protein.
REFERENCES:
patent: 5716821 (1998-02-01), Wertz et al.
patent: 5789229 (1998-08-01), Wertz et al.
patent: 5869036 (1999-02-01), Belshe et al.
patent: 5882651 (1999-03-01), Murphy et al.
patent: 5922326 (1999-07-01), Murphy et al.
patent: 5993824 (1999-11-01), Murphy et al.
patent: 6033886 (2000-03-01), Conzelmann
patent: 0 440 219 (1991-08-01), None
patent: 0 702 085 (1996-03-01), None
patent: WO 93/14207 (1993-07-01), None
patent: WO 93/21310 (1993-10-01), None
patent: WO 97/06270 (1997-02-01), None
patent: WO 97/11093 (1997-03-01), None
patent: WO 97/12032 (1997-04-01), None
patent: WO 97/20468 (1997-06-01), None
patent: WO 98/02530 (1998-01-01), None
patent: WO 98/43668 (1998-10-01), None
patent: WO 98/53078 (1998-11-01), None
patent: WO 99/02657 (1999-01-01), None
patent: WO 99/15631 (1999-04-01), None
patent: WO 00/61611 (2000-10-01), None
patent: WO 00/61737 (2000-10-01), None
patent: WO 01/04271 (2001-01-01), None
patent: WO 01/04321 (2001-01-01), None
Bukreyev et al. (Journal of Virology, 2005, 79(15):9515-9526).
Bukreyev et al. (Journal of Virology, 2001, 75(24) :12128-121240).
Bukreyev et al. (PNAS USA, 2002, 99(26):16987-16991).
Bailly et al., “A Recombinant Human Parainfluenza Virus Type 3 (PIV3) in Which the Nucleocapsid N Protein Has Been Replaced by That of Bovine PIV3 Is Attenuated in Primates,”J. Virol.74(7):3188-3195, 2000.
Baron et al., “Rescue of Rinderpest Virus from Cloned cDNA,”J. Virol.71:1265-1271, 1997.
Bembridge et al., “Recombinant Vaccinia Virus Coexpressing the F Protein of Respiratory Syncytial Virus (RSV) and Interleukin-4 (IL-4) Does Not Inhibit the Development of RSV-Specific Memory Cytotoxic T Lymphocytes, whereas Priming is Diminished in the Presence of High Levels of IL-2 or Gamma Interferon,”J. Virol.72:4080-4087, 1998.
Bermingham et al.; “The M2-2 Protein of Human Respiratory Syncytial Virus is a Regulatory Factor Involved in the Balance Between RNA Replication and Transcription,”Proc. Natl. Acad. Sci. USA96:11259-11264. 1999.
Buchholz et al., “Generation of Bovine Respiratory Syncytial Virus (BRSV) from Cdna: BRSV NS2 Is Not Essential for Virus Replication in Tissue Culture, and the Human RSV Leader Region Acts as a Functional BRSV Genome Promoter,”J. Virol.73:251-259, 1999.
Buchholz et al., “Chimeric Bovine Respiratory Syncytial Virus with Glycoprotein Gene Substitutions from human Respiratory Syncytial Virus (HRSV): Effects on Host Range and Evaluation as a Live-Attenuated HRSV Vaccine,”J. Virol.74:1187-1199, 2000.
Bukreyev, et al., “Recovery of Infectious Respiratory Syncytial Virus Expressing an Additional, Foreign Gene,”J. Virol.70:6634-41, 1996.
Bukreyev, et al., “Recombinant Respiratory Syncytial virus from which the Entire SH Gene has been Deleted Grows Efficiently in Cell Culture and Exhibits Site-Specific Attenuation in the Respiratory Tract of the Mouse,”J. Virol.71:8973-8982, 1997.
Bukreyev, et al., “Interferon γ Expressed by a Recombinant Respiratory Syncytial Virus Attenuates Virus Replication in Mice Without Compromising Immunogenicity,”Proc. Nat. Acad. Sci. USA96:2367-2372, 1999.
Collins et al., “Rescue of Synthetic Analogs of Respiratory Syncytial Virus Genomic RNA and Effect of Truncations and Mutations on the Expression of a Foreign Reporter Gene,”Proc. Natl. Acad. Sci. USA, 88:9663-9667, 1991.
Collins, et al., “Rescue of a 7502-Nucleotide (49.3% of Full-Length) Synthetic Analog of Respiratory Syncytial Virus Genomic RNA,”Virology195:252-256, 1993.
Collins et al., “Production of Infectious Human Respiratory Syncytial Virus from Cloned cDNA Confirms an Essential Role of the Transcription Elongation Factor from the 5′ Proximal Open Reading Frame of the M2 mRNA in Gene Expression and Provides a Capability for Vaccine Development,”Proc Nat. Acad. Sci. USA92:11563-11567, 1995.
Collins et al., “Support Plasmids and Support Proteins Required for Recovery of Recombinant Respiratory Syncytial Virus,”Virology259:251-255, 1999.
Conzelmann et al., “Rescue of Synthetic Genomic RNA Analogs of Rabies Virus by Plasmid-Encoded Proteins,”J. Virol.68:713-719, 1994.
Conzelmann, “Genetic Manipulation of Non-Segmented Negative-strand RNA Viruses,”J. Gen. Virol.77:381-389, 1996.
Crowe, et al., “A Further Attenuated Derivative of a Cold-Passaged Temperature-Sensitive Mutant of Human Respiratory Syncytial Virus Retains Immunogenicity and Protective Efficacy Against Wild-Type Challenge in Seronegative Chimpanzees,”Vaccine12:783-790, 1994.
Crowe, et al., “Acquisition of thetsPhenotype by a Chemically Mutagenized Cold-Passaged Human Respiratory Syncytial Virus Vaccine Candidate Results from the Acquisition of a Single Mutation in the Polymerase (L) Gene,”Virus Genes13:269-273, 1996.
Delenda, et al., “Normal Cellular Replication of Sendai Virus Without thetrans-Frame, Nonstructural V Protein,”Virology228:55-62, 1997.
Durbin et al., “Recovery of Infectious Human Parainfluenza Virus Type 3 from cDNA,”Virology235:323-332, 1997.
Finke and Conzelmann, “Ambisense Gene Expression from Recombinant Rabies Virus: Random Packaging or Positive- and Negative-Strand Ribonucleoprotein Complexes into Rabies Virions,”J. Virol.71:7281-7288, 1997.
Flexner et al., “Prevention of Vaccinia Virus Infection in Immunodeficient Mice by Vector-Directed IL-2 Expression,”Nature330:259-262,1987.
Flexner et al., “Attenuation and Immunogenicity in Primates of Vaccinia Virus Recombinants Expressing Human Interleukin-2,”Vaccine8:17-21, 1990.
Garcia-Sastre et al., “Use of a Mammalian Internal Ribosomal Entry Site Element for Expression of a Foreign Protein by a Transfectant Influenza Virus,”J. Virol.68:6254-6261, 1994.
Garcin et al., “A Highly Recombinogenic System for the Recovery of Infectious Sendai Paramyxovirus from cDNA: Generation of Novel Copy-back Nondefective Interfering Virus,”EMBO J.14:6087-6094, 1995.
Giavedoni et al., “Expression of Gamma Interferon by Simian Immunodeficiency Virus Increases Attenuation and Reduces Postchallenge Virus Load in Vaccinated Rhesus Macaques,”J. Virol.71:866-872, 1997.
Grundlach et al., “Construction, Replication, and Immunogenic Properties of a Simian Immunodeficiency Virus Expressing Interleukin-2,”J. Virol.71:2225-2232, 1997.
He et al., “Recovery of Infectious SV5 from Cloned DNA and Expression of a Foreign Gene,”Virology237:249-260, 1997.
He et al., “The Paramyxovirus SV5 Small Hydrophobic (SH) Protein is not Essential for Virus Growth in Tissue Culture Cells,”Virology250:30-40, 1998.
Hendricks et al., “Further Characteristics of the Soluble Form of the G Glycoprotein of Respiratory Syncytial Virus,”J. Virol.62:2228-2233, 1988.
Hoffman et al., “An Infectious Clone of Human Parainfluenza Virus Type 3,”J. V
Bukreyev Alexander
Collins Peter L.
Murphy Brian R.
Whitehead Stephen S.
Birch & Stewart Kolasch & Birch, LLP
Chen Stacy B
The United States of America as represented by the Department of
LandOfFree
Polynucleotides encoding recombinant respiratory syncytial... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polynucleotides encoding recombinant respiratory syncytial..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotides encoding recombinant respiratory syncytial... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4023254